Gilead Sciences Current Ratio 2006-2021 | GILD

Current and historical current ratio for Gilead Sciences (GILD) from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Gilead Sciences current ratio for the three months ending June 30, 2021 was 1.36.
Gilead Sciences Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $13.93B $10.21B 1.36
2021-03-31 $13.28B $9.71B 1.37
2020-12-31 $16.00B $11.40B 1.40
2020-09-30 $30.93B $9.51B 3.25
2020-06-30 $24.64B $10.56B 2.33
2020-03-31 $26.95B $8.88B 3.04
2019-12-31 $30.30B $9.76B 3.10
2019-09-30 $28.36B $9.57B 2.96
2019-06-30 $33.73B $8.96B 3.76
2019-03-31 $34.02B $9.40B 3.62
2018-12-31 $35.84B $10.61B 3.38
2018-09-30 $34.92B $10.12B 3.45
2018-06-30 $32.73B $10.91B 3.00
2018-03-31 $30.26B $10.67B 2.84
2017-12-31 $31.82B $11.64B 2.74
2017-09-30 $35.32B $9.60B 3.68
2017-06-30 $28.59B $8.49B 3.37
2017-03-31 $21.42B $8.28B 2.59
2016-12-31 $19.59B $9.22B 2.13
2016-09-30 $21.43B $11.07B 1.94
2016-06-30 $18.35B $10.44B 1.76
2016-03-31 $19.27B $10.91B 1.77
2015-12-31 $24.76B $9.89B 2.50
2015-09-30 $25.91B $9.36B 2.77
2015-06-30 $18.09B $8.93B 2.03
2015-03-31 $20.06B $7.43B 2.70
2014-12-31 $17.71B $5.76B 3.08
2014-09-30 $12.56B $6.06B 2.08
2014-06-30 $15.50B $6.23B 2.49
2014-03-31 $12.97B $5.92B 2.19
2013-12-31 $7.00B $6.41B 1.09
2013-09-30 $6.97B $4.90B 1.42
2013-06-30 $7.07B $4.94B 1.43
2013-03-31 $6.66B $4.29B 1.55
2012-12-31 $6.16B $4.24B 1.45
2012-09-30 $5.88B $4.80B 1.23
2012-06-30 $5.84B $4.99B 1.17
2012-03-31 $5.83B $4.19B 1.39
2011-12-31 $13.92B $2.52B 5.54
2011-09-30 $6.15B $2.22B 2.76
2011-06-30 $6.22B $2.31B 2.69
2011-03-31 $6.85B $2.77B 2.47
2010-12-31 $5.71B $2.47B 2.32
2010-09-30 $6.03B $2.59B 2.33
2010-06-30 $5.71B $3.11B 1.84
2010-03-31 $5.12B $1.89B 2.72
2009-12-31 $4.81B $1.87B 2.57
2009-09-30 $4.30B $1.89B 2.28
2009-06-30 $4.00B $1.78B 2.25
2009-03-31 $4.62B $1.26B 3.66
2008-12-31 $4.28B $1.22B 3.50
2008-09-30 $4.33B $1.26B 3.44
2008-06-30 $3.67B $2.45B 1.50
2008-03-31 $2.95B $0.94B 3.14
2007-12-31 $3.03B $0.74B 4.11
2007-09-30 $2.55B $0.69B 3.68
2007-06-30 $2.45B $0.75B 3.26
2007-03-31 $2.44B $0.71B 3.44
2006-12-31 $2.43B $0.76B 3.18
2006-09-30 $4.03B $0.58B 6.93
2006-06-30 $2.49B $0.51B 4.91
2006-03-31 $3.38B $0.42B 8.00
2005-12-31 $3.09B $0.47B 6.65
2005-09-30 $2.30B $0.27B 8.58
2005-06-30 $2.39B $0.26B 9.13
2005-03-31 $2.07B $0.27B 7.66
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $89.497B $24.689B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71